tbuckley/cabot-search huggingface dataset:
Presentation of Papers—A Just Criticism.
Authors: None B.
Journal: JAMA (1906)

Chicago, June 16, 1906. <h3>To the Editor:</h3> —While we are still enthusiastic over the wonderful success of the Boston session and thoroughly impressed with the dignity and great efficiency of the machinery of the American Medical Association, would it not be well to consider some of the factors which have operated to qualify the complete satisfactoriness in some directions? It is obvious that the growth and general development of the Association is to present new problems which so far as may be should be anticipated. The sections, particularly in medicine and surgery, are and are destined to be still more attended to a degree that makes the complete usefulness difficult to achieve. The presentation of the formal paper necessarily is acquiring a greater prominence and the discussion by the general profession, which in former days was one of the chief pleasures, to say the least, of the session, is becoming
A phase I trial of E7974 administered on days 1, 8, and 15 of a 28-day cycle in patients with solid malignancies
Authors: N. J. Zojwalla, C. H. Takimoto, A. G. Lucarelli, R. Clark, A. C. Mita, M. M. Mita, O. Romero, E. L. Schuck, I. Krivelevich, C. J. Sweeney
Journal: Journal of Clinical Oncology (2007)

2543 Background: E7974 is a synthetic hemiasterlin analogue exhibiting binding to a and β tubulin. It induces disruption of spindle formation and mitotic arrest characteristic of anti-tubulin cancer drugs. Unlike taxanes and vincas, E7974 is a poor substrate for the PgP drug efflux pump, potentially overcoming this common mechanism of drug resistance. E7974 demonstrates broad anti-tumor activity against a number of human tumor xenografts. Methods: We conducted the initial Phase I trial using an accelerated dose escalation design to determine the maximum tolerated dose (MTD) and pharmacokinetic (PK) profile of E7974 administered IV over 2–5 minutes on Days 1, 8, and 15 of a 28-day cycle. Results: Sixteen patients (7 male, 9 female) with a variety of tumor types and a median age of 54 yrs.(range: 33–78 yrs) were treated at doses of 0.15 mg/m 2 , 0.21 mg/m 2 , and 0.29 mg/m 2 . In the accelerated phase, 0.15 mg/m 2 and 0.21 mg/m 2 were tolerated. At the 0.29 mg/m 2 dose level, one patient experienced grade 4 neutropenia after Day 8. Expansion of the 0.21 mg/m 2 dose level resulted in one patient experiencing grade 4 neutropenic fever. Two other patients experienced grades 2 and 3 neutropenia, resulting in delayed dosing beyond Cycle 1. Five additional patients were treated at 0.15 mg/m 2 ; none experienced a DLT or dose delay, thus confirming 0.15 mg/m 2 as the MTD. Other observed drug- related toxicities included mild to moderate fatigue, nausea, vomiting, constipation, neuropathy, and myalgias. The PK profile of E7974 can be characterized by moderate to large distribution (Vss = 50 - 133 L), slow clearance (CL = 1.4 - 9 L/hr) and moderate to slow elimination (t 1/2 = 6.3 - 31 hr). Approximately 34 - 84% of the administered dose was recovered unchanged in the urine 48 hours post-dose. Stable disease was seen in one patient with colorectal cancer (6 cycles). The MTD cohort has been expanded to a total of 16 evaluable patients for confirmation of tolerability and PK. Conclusions: The recommended Phase 2 dose on Days 1, 8, and 15 of a 28-day schedule is 0.15 mg/m 2 . Observed toxicities were manageable and reversible. Enrollment is ongoing. [Table: see text]
BOOK REVIEWS
Authors: W. D. Travis
Journal: JNCI Journal of the National Cancer Institute (1992)

Journal Article BOOK REVIEWS Get access Tumours: Structure and Diagnosis R. C. Curran , E. L. Jones . Oxford : Oxford Univ. Press . 1991 . 812 pp., illus. $275 William D. Travis William D. Travis National Cancer Institute National Institutes of Health Bldg.10, Rm, 2N218 Bethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 11, 3 June 1992, Page 896, https://doi.org/10.1093/jnci/84.11.896 Published: 03 June 1992
JAMA Cardiology
Authors: Phil Fontanarosa, Annette Flanagin, Brenda Gregoline, Tracy Frey, Iris Lo, Kevin Brown, Amanda Ehrhardt, M Newman, Suzanne Walker, Connie Manno Senior, Sara Billings, Timothy Gray, Juliet Orellana, Paul Ruich, Kirby Snell, Catherine Alden, Stephanie Beckmeyer, Jane Calayag, Jan Clavey, Mary Coerver-Connolly, Paula Glitman, Laura King, Regina Lilly, Charon Pierson, Rebecca Ritke, Thressa Smith, Divya Sreekumar, Donna Thordsen, Christine Tilles, Caroline Woods, Editorial Assistant, Wanda Hill, Larry Bryant, Jacob Kendall-Taylor, Monica Managers, Fanny Staff, Anna Brown, Lee Bukowski, Lenette Calibeo, Tosca Gardner-Gullens, Erin Hall, Rachell Kato, Caroline Lozano, Angelia Sietmann, Michael Berkwits, Eric Butkus, Jesse Mcquarters, Elena Guobyte, Emily Ling, Daniel Morrow, Social Media, Eman Hassaballa, Reuben Rios, Mary Ferkaluk, Karen Bucher, Andy Rekito, Nick Reback, Lohitha Kethu, David Song, Deputy Livingston, Thomas Cole, Marla Hall, Deanna Willis, Yolanda Davis, Joseph Thornton, Deanna Bellandi, Jim Periodical, Thomas Easley, Brian Shields, Karen Adams-Taylor, Paul Gee, Monica Smith, Jeff Ery, J Bonistalli, Kathy Russell, Mirna Monal, Stacey Mchugh, Tim Melroy, Marketing Thornbury, Tricia Castellano, Anna Manager, Thalia Moss, Sade Deramus-Townsend, Tony Ralenkotter, Marsha Fogler, Rachel Sisholtz, Saskia Bolore, Gretchen Linder, Brian Mccartney, Christine Hearne, Natasha Staff, Henry Aguillon, David Baum, Ron Thomas, Rick Bell, Elizabeth Solaro, Sara Zimmerman, Geoff Rey, Lindsay Dawson, Ellen Gibson, Sam Ismail, Craig Mccaff Rey, Michael Mcgraw, Daniel Pickhardt, Romando Rossini, Sarah Subramanian, Stacy Business, Analyst Sirisha, Alluri Staff, Millette Jackson-Bates, Tom Miller, Morgan Osgood, James Madara, Howard Bauchner, Robert Bonow, Patrick O'gara, Marc Sabatine, Clyde Boston, Michael Pencina, Carolina North, Adrian Hernandez, Mhs Durham, North Carolina, Mark Huff Man, Ajay Kirtane, New York, Roxana Mehran, Ann Navar, Carolina Christopher, J O'donnell, Massachusetts Boston, J Sanjiv, Mintu Shah, Gregg Fonarow, Los Angeles, Elizabeth Mcnally, Laine Thomas, Julia Getts, Eugene Braunwald, Robert Califf, Judith Hochman, Donald Lloyd-Jones, Scm Chicago, Michael Parmacek, Daniel Simon, Sidney Smith, Chapel Hill, Carolina Douglas, E Vaughan, Myron Weisfeldt, Maryland Douglas, P Zipes, Paul Armstrong, Shinya Goto, Peter Liu, Renato Lopes, Carolina Maseri, Dorairaj Prabhakaran, Hugh Watkins, Harvey White, Habib Yacoub
Journal: JAMA Cardiology (2019)
Breathtaking Research: Dangers in the Air We Breathe
Authors: Mike May
Journal: Environmental Health Perspectives (2000)

Although the air we breathe is necessary for life, certain factors may make this same air detrimental to our health. For instance, a seemingly endless list of compounds can be toxic at certain concentrations, and inhaling such compounds may lead to damage in different parts of the body. To investigate the particular effects of inhaled toxicants, the NIEHS developed the Respiratory Toxicology Group. The group, which consists of toxicologist Dan Morgan, biologist Cassandra Shines, and engineer Michael Moorman, has been conducting experiments for about a decade at the NIEHS inhalation facility. Morgan says the group typically conducts studies of chemicals that have been nominated to the National Toxicology Program for investigation into their carcinogenic potential and other end points.
Commentary
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Does this patient have an alcohol problem?
Authors: J. M. Kitchens
Journal: JAMA (1994)

<h3>CLINICAL SCENARIO</h3> A 58-year-old man was admitted to the hospital for an elective cholecystectomy. At the time of admission, he smelled of alcohol, although he was not obviously intoxicated. On questioning he said he had come from a business lunch where he had "a drink." When questioned about his alcohol history he became angry and defensive. He said he was "offended by the implications of these questions." On the day following surgery he was found to be diaphoretic, tremulous, and hallucinating and was judged to be in alcohol withdrawal. Could other interviewing techniques have identified this man as one who was alcohol dependent and at risk of withdrawal? <h3>WHY IS THIS AN IMPORTANT QUESTION TO ANSWER WITH A CLINICAL EXAMINATION?</h3> It is estimated that more than 100 million Americans drink alcohol and that about 10% of those who drink have alcohol problems that adversely affect their lives and the lives
MANAGEMENT OF ACUTE LEUKEMIA: A CLUE FROM AFRICA
Journal: JAMA (1966)

The implications of Burkett's lymphoma to our understanding of childhood leukemia become more and more apparent. That the two are indeed closely related was first suggested by their geographic, reciprocal relationship, the similarity of the tumor cells, their usual origin in bone marrow, and the minor differences in their natural histories which can best be interpreted in terms of host resistance. The lymphomas of African children occur somewhat later in life, are more localized, and run a more protracted course.<sup>1</sup>Both are responsive to a remarkable degree to chemotherapy, the Burkitt variety being the more responsive. Long-term remissions are achieved in 0.5% to 1% of acute leukemia patients; in the African lymphomas, perhaps ten times as frequently. The antibody reactions recently demonstrated in the Burkitt variety were discussed in a recent editorial<sup>2</sup>and seem to be a measure of the postulated host resistance. The presence of antibody and
Occult celiac disease as a cause of iron deficiency anemia
Authors: Z. M. Kilpatrick
Journal: JAMA (1969)

Occult celiac disease was the cause of chronic iron deficiency anemia in two women who did not have clinically apparent malabsorption. There had been no response to oral administration of iron and neither had had abnormal blood loss. Iron deficiency anemia that is refractory to oral iron therapy may be due to celiac disease. Tests of intestinal absorption and biopsy of the small bowel are indicated.
Analysis of the Effects of Overexpression of Metallothionein-I in Transgenic Mice on the Reproductive Toxicology of Cadmium
Authors: Tim Dalton, Kai Fu, George C. Enders, Richard D. Palmiter, Glen K. Andrews
Journal: Environmental Health Perspectives (1996)

Exposure to low levels of cadmium reduces fertility. In male mice spermatogenesis is highly sensitive to cadmium, whereas in females the peri-implantation period of pregnancy is sensitive. To examine the potential roles of the cadmium-binding protein, metallothionein (MT), in the reproductive toxicology of cadmium, we examined a transgenic mouse strain that overexpresses metallothionein-I (MT-I). These mice had dramatically increased steady-state levels of MT-I mRNA and MT in the testes and in the female reproductive tract during the peri-implantation period of pregnancy, and this overexpression occurred in a cell-specific and temporally regulated manner similar to that of the endogenous MT-I gene. Transgenic and control males were injected with cadmium, and the histology of the testes was examined. An injection of 7.5 mumol Cd/kg had no effect on histology of the testes in either transgenic or control mice. In contrast, an injection of 10 mumol Cd/kg caused rapid changes in the histology of the testes and resulted in pronounced testicular necrosis in both control and transgenic mice. Female transgenic and control mice were mated and then injected with cadmium (30-45 mumol Cd/kg) on the day of blastocyst implantation (day 4). In both of these groups, injection of cadmium reduced pregnancy rate, and no dramatic protection was afforded by maternal and/or embryonic overexpression of MT. Thus, overexpression of MT-I does not significantly protect against either of these cadmium-induced effects on fertility.
DIARRHEA AND ANHYDREMIA IN INFANCY
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 4589: Clinical significance of the EML4-ALK fusion gene and association with EGFR and KRAS gene mutation in 208 Chinese patients with non-small cell lung cancer
Authors: Jun Chen, Hongyu Liu, tong Yang, Sen Wei, Ying Li, Yuli Wang, Yongwen Li
Journal: Cancer Research (2012)

Abstract Objective: EML4-ALK fusion gene is a potentially relevant oncogenic event in lung cancer, which represents a new subgroup of non-small cell lung cancer (NSCLC) patients who respond positively to ALK inhibitors. The characteristics of EML4-ALK fusion gene in Chinese Patients with NSCLC are poorly understood. In this study, we aimed to analyze the prevalence of EML4-ALK fusion gene and their correlation to epidermal growth factor receptor (EGFR) status, KRAS mutation, and clinico-pathological data in Chinese patients with NSCLC. Methods: EML4-ALK fusion gene was detected by nested RT-PCR and confirmed by sequencing. EGFR and KRAS gene status were evaluated by RT-PCR and sequencing. Survival analysis was performed. A meta-analysis of the EML4-ALK fusion gene in lung cancer patients was also presented. Results: Two hundred eight NSCLC cases were evaluated. There were 51 cases of mutations in EGFR at exons 18-21 (24.5%, 51/208). Among exons 18-21, EGFR mutations occur predominantly (92%) in exons 19 and 21. In concordance with previous reports, these mutations are identified at high frequencies in females (47.5%, 29/61 vs 15.0%, 22/147 in males; P = 0.000); never-smokers (42.3%, 33/78 vs 13.9%, 18/130 in smokers; P = 0.000), and adenocarcinoma patients (44.2%, 42/95 vs 8.0%, 9/113 in non-adenocarcinoma patients; P = 0.000). There were only 6 cases (6/208, 2.88%) of KRAS mutations in our study group. We identified 7 patients who harbored the EML4-ALK fusion gene (3.37%, 7/208) which all confirmed by DNA sequencing. Of these 7 patients, 2 cases displayed the EML4-ALK variant 1 (28.6%), 1 case exhibited variant 2 (14.3%) and 4 cases carried variant 3 (57.1%). All of the positive cases corresponded to female patients (11.5%, 7/61). Six of the positive cases were non-smokers (7.69%, 6/78). The incidence of EML4-ALK translocation in female non-smoking adenocarcinoma patients is as high as 15.2% (5/33). No EGFR/KRAS mutations were detected among EML4-ALK positive patients. The meta-analysis demonstrated that EML4-ALK translocation was 4.71% (125/2652) in unselected patients with NSCLC, and was also predominant in female patients with adenocarcinoma. Conclusion: EML4-ALK translocations are infrequent in the entire NSCLC patient population, but are frequent in the NSCLC patient subgroup of female, nonsmokers, and adenocarcinoma patients. Our results indicate that the detection of the EML4-ALK translocation in subgroups of patients with NSCLC is crucial for applying targeted therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4589. doi:1538-7445.AM2012-4589
Prothrombin mutant, factor V Leiden, and thermolabile variant of methylenetetrahidrofolate reductase among patients with sickle cell disease in Brazil
Authors: Fernanda L. Andrade, Joyce M. Annichino-Bizzacchi, Sara T. O. Saad, Fernando F. Costa, Valder R. Arruda
Journal: American Journal of Hematology (1998)
THE ELIMINATION OF INFECTIOUS MICROBES FROM THE DISEASED BODY.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
END-RESULTS IN TREATMENT OF KNEE JOINT TUBERCULOSIS
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Unshielded Genitalia
Authors: George W. Anstadt
Journal: JAMA (1976)

<h3>To the Editor.—</h3> In the article entitled "Slipped Femoral Epiphysis: Occurrence After Treatment With Chronic Gonadotropin" (235:751, 1976), a roentgenogram of the hip of a 17year-old youth shows the contour of the unshielded genitalia. This constitutes a poor practice that should not be given acceptibility by publication.
Correction: The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE"
Authors: Peter Savas, Zhi Ling Teo, Christophe Lefevre, Christoffer Flensburg, Franco Caramia, Kathryn Alsop, Mariam Mansour, Prudence A. Francis, Heather A. Thorne, Maria Joao Silva, Nnennaya Kanu, Michelle Dietzen, Andrew Rowan, Maik Kschischo, Stephen Fox, David D. Bowtell, Sarah-Jane Dawson, Terence P. Speed, Charles Swanton, Sherene Loi
Journal: PLoS Medicine (2017)

[This corrects the article DOI: 10.1371/journal.pmed.1002204.].
In vivo effects of illicit hallucinogens on human lymphocyte chromosomes
Authors: D. Dorrance
Journal: JAMA (1970)

Fourteen subjects exposed to illicit lysergic acid diethylamide (LSD) and nine exposed to marihuana were compared to age-matched controls for effects upon lymphocyte chromosomes. Eight out of 1,284 in the group given LSD, or 0.76%, exhibited chromosomal abnormalities; seven out of 816, or 0.86%, in the group given marihuana; and eight out of 1,018, or 0.79%, in the control group. Cells were grown in medium unenriched with nucleotide precursors. Thus, our negative results mitigate against medium deficiency as contributing toward positive effects. Similarly, our results on individuals whose last dosage was within an hour or so of specimen procurement indicates that this factor may not explain conflicting results.
Urological evaluation
Authors: H. N Whitfield
Journal: BMJ (2006)

The most common urological complaints that need referral to a primary care doctor or urological surgeon can be divided into those referable to the lower urinary tract and those referable to the upper urinary tract.Although a careful history may be diagnostic in patients with, for example, renal colic or testicular torsion, often non-specific features are more difficult to unravel.
Cutaneous necrosis caused by systemically administered heparin
Authors: R. A. Kelly
Journal: JAMA (1981)

Two cases of cutaneous necrosis occurred that were caused by intravenous administration of porcine heparin for deep venous thrombophlebitis. The lesions grossly resembled those of warfarin sodium-induced skin necrosis. However, histologically, no fibrin thrombi were noted in capillaries and vessels, a characteristic finding in warfarin necrosis. There was no evidence of vasculitis in the lesions. Both patients subsequently received warfarin without complications. (<i>JAMA</i>1981;246:1582-1583)
Web-based stress management for newly diagnosed cancer patients (STREAM): A randomized, wait-list controlled intervention study.
Authors: Viviane Hess, Astrid Grossert (equal contributor), Judith Alder, Sandra Scherer, Barbara Handschin, Borislava Borislavova, Sven Degen, Alexandra Faessler, Jennifer Hartung, Sarah Schibli, Celine Werndli, Jens Gaab, Thomas Berger, Thomas Zumbrunn, Corinne Urech
Journal: Journal of Clinical Oncology (2017)

LBA10002 The full, final text of this abstract will be available at abstracts.asco.org at 2:00 PM (EDT) on Friday, June 2, 2017, and in the Annual Meeting Proceedings online supplement to the June 20, 2017, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.